Tag: In the News,ddPCR,droplet digital PCR,liquid biopsy,liquid biopsy vs tissue biopsy,lung cancer

  “In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians who are evaluating an NSCLC patient’s eligibility for anti-PD-L1 therapy.” Read the full story. 

  “These promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test as well as the possibility of identifying a meaningful, clinically relevant threshold for the assay. Consequently, Biodesix has combined with collaborators in its physician network, including FirstHealth Moore Regional Hospital and Pinehurst Medical Clinic, to validate the assay by analyzing…

  “I see ddPCR as the future of personalized cancer therapies. Based on our cancer center’s successful experience with the technology, I believe it is only a matter of time before these kinds of blood-based liquid biopsies become an indispensable method for doctors to categorize a patient’s disease and determine the best course of treatment.”…

“We can now identify a cancer’s mutations and respond with appropriate therapy without the issues inherent in solid tissue biopsy – not only the delays, but also the intratumoral heterogeneity that is often missed when sampling only one or a few tumor sites.” – Dr. Paul Walker Read the full story. 

“The clinical course of newly diagnosed, advanced NSCLC can be rapid, with prognoses typically measured in months. Early intervention with appropriately targeted therapies can increase the overall chance of survival, and therefore speed is critical when obtaining biomarker information that might influence the design and initiation of a therapeutic strategy. However, the results from tumor…